Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Peter Greenleaf Sells 797 Shares

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $26.13, for a total value of $20,825.61. Following the completion of the transaction, the director owned 23,884 shares in the company, valued at $624,088.92. This trade represents a 3.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 1.1%

Pelthos Therapeutics stock opened at $24.60 on Wednesday. Pelthos Therapeutics Inc. has a twelve month low of $16.09 and a twelve month high of $37.50. The stock’s 50 day moving average is $26.77. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41. The firm has a market cap of $85.61 million, a PE ratio of -1.19 and a beta of 3.10.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The firm had revenue of $10.91 million during the quarter. Equities analysts predict that Pelthos Therapeutics Inc. will post -12.63 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price objective for the company. Finally, Oppenheimer lifted their price objective on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $55.80.

Hedge Funds Weigh In On Pelthos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC lifted its stake in shares of Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after purchasing an additional 193,307 shares during the period. Boothbay Fund Management LLC grew its position in Pelthos Therapeutics by 279.8% during the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after buying an additional 59,435 shares during the period. J. Goldman & Co LP purchased a new position in Pelthos Therapeutics in the fourth quarter valued at about $2,418,000. Cantor Fitzgerald L. P. acquired a new stake in shares of Pelthos Therapeutics during the 4th quarter valued at approximately $1,085,000. Finally, Diadema Partners LP boosted its stake in shares of Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares in the last quarter. 77.96% of the stock is owned by institutional investors and hedge funds.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).